These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21386788)

  • 1. Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy.
    Cremonesi M; Ferrari M; Di Dia A; Botta F; De Cicco C; Bodei L; Paganelli G
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):155-67. PubMed ID: 21386788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry in Peptide radionuclide receptor therapy: a review.
    Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
    J Nucl Med; 2006 Sep; 47(9):1467-75. PubMed ID: 16954555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides.
    Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):288-95. PubMed ID: 17043626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetry in nuclear medicine therapy: radiobiology application and results.
    Strigari L; Benassi M; Chiesa C; Cremonesi M; Bodei L; D'Andrea M
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):205-21. PubMed ID: 21386791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead.
    Walrand S; Jamar F
    Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry for treatment with radiolabelled somatostatin analogues. A review.
    Cremonesi M; Botta F; Di Dia A; Ferrari M; Bodei L; De Cicco C; Rossi A; Bartolomei M; Mei R; Severi S; Salvatori M; Pedroli G; Paganelli G
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):37-51. PubMed ID: 20168285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.
    Baechler S; Hobbs RF; Boubaker A; Buchegger F; He B; Frey EC; Sgouros G
    Med Phys; 2012 Oct; 39(10):6118-28. PubMed ID: 23039651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From imaging to dosimetry and biological effects.
    Konijnenberg M
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):44-56. PubMed ID: 21386784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
    Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
    J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidates for peptide receptor radiotherapy today and in the future.
    Reubi JC; Mäcke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.
    Pauwels S; Barone R; Walrand S; Borson-Chazot F; Valkema R; Kvols LK; Krenning EP; Jamar F
    J Nucl Med; 2005 Jan; 46 Suppl 1():92S-8S. PubMed ID: 15653657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical studies of peptide receptor radionuclide therapy.
    Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M
    Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry.
    Traino AC; Ferrari M; Cremonesi M; Stabin MG
    Phys Med Biol; 2007 Sep; 52(17):5231-48. PubMed ID: 17762083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of dose with toxicity and tumour response to
    Cremonesi M; Ferrari ME; Bodei L; Chiesa C; Sarnelli A; Garibaldi C; Pacilio M; Strigari L; Summers PE; Orecchia R; Grana CM; Botta F
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2426-2441. PubMed ID: 29785514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical dosimetry in the treatment of bone tumors: old and new agents.
    Hindorf C; Flux GD; Ibisch C; Kraeber Bodéré F
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):198-204. PubMed ID: 21386790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations.
    Sarnelli A; Guerriero F; Botta F; Ferrari M; Strigari L; Bodei L; D'Errico V; Grassi E; Fioroni F; Paganelli G; Orecchia R; Cremonesi M
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):216-231. PubMed ID: 26576734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors.
    Krenning EP; Teunissen JJ; Valkema R; deHerder WW; deJong M; Kwekkeboom DJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):146-50. PubMed ID: 16625865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention.
    Vegt E; de Jong M; Wetzels JF; Masereeuw R; Melis M; Oyen WJ; Gotthardt M; Boerman OC
    J Nucl Med; 2010 Jul; 51(7):1049-58. PubMed ID: 20554737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretherapy prediction of nephrotoxicity after peptide radionuclide receptor therapy (PRRT).
    Denardo GL; Macey DJ
    Cancer Biother Radiopharm; 2010 Oct; 25(5):507-9. PubMed ID: 20849311
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor control probability for tumor therapy with beta radionuclide interstitial injection.
    Chen Y; Geng J; Tian J; He Y; Chen S
    Biomed Mater Eng; 2004; 14(3):333-5. PubMed ID: 15299245
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.